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OBJECTIVE: To assess the predictive value of quantitative fetal fibronectin (fFN) 
concentration in cervicovaginal fluid for spontaneous preterm birth in women with bulging 
fetal membranes.
STUDY DESIGN: This was a prospective observational study from five UK tertiary centres of a 
cohort of women with singleton pregnancy and bulging fetal membranes presenting 
between 18 and 32 weeks of gestation (n=62), in the period 2010-2014. fFN concentrations 
in cervicovaginal fluid were measured both quantitatively and qualitatively at presentation 
in all women. Predictive statistics and receiver operating characteristic (ROC) curves were 
calculated for both tests to predict spontaneous preterm birth within 14 days from testing 
and before 34 weeks of gestation.
RESULTS: 62 eligible women with bulging fetal membranes were recruited from screening of 
2571 women at high risk of preterm birth. The median gestational age was 24+0 (LQ-UQ, 
21+2-25+3) at presentation and 34+4 (25+2-39+0) at delivery, with a median time from testing 
to delivery of 58 days (17-110). Concentration of quantitative fFN at presentation correlated 
negatively with time to delivery (Spearman’s rs=-0.615, p<0.001). The area under the ROC 
curve for quantitative fFN testing was 0.81 (95% CI 0.69-0.94) for prediction of spontaneous 
preterm birth within 14 days, and 0.84 (0.73-0.95) before 34 weeks of gestation.
CONCLUSION: Quantitative fFN has a role in predicting spontaneous preterm birth even in 
women with bulging fetal membranes, suggesting that fFN leakage could potentially be an 
active process. This may aid the clinical management of this high-risk group in the future.
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Condensation: Quantitative fetal fibronectin can help predict spontaneous preterm birth 
even in the presence of bulging fetal membranes. 
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INTRODUCTION
Preterm birth is the leading cause of neonatal mortality globally, directly responsible for 
over 15% of all neonatal deaths as well as short and long-term morbidity and disability [1,2]. 
Interventions such as timely antenatal steroid administration and in-utero transfer to 
specialist units have been shown to improve neonatal mortality and morbidity [3,4]. In 
women with bulging fetal membranes (BFM) at early gestations – a particularly high-risk 
group – the use of rescue cervical cerclage can delay delivery by approximately 5 weeks [5–
7]. However, this frequently fails and could increase the risk of infection to mother and 
fetus; furthermore, some women presenting with BFM do not deliver prematurely even 
without intervention [8].
A bedside test for the analysis of fetal fibronectin (fFN) concentration in cervicovaginal fluid 
(CVF) (Hologic Rapid fFN TLiIQ) can help predict spontaneous preterm birth (sPTB) in 
symptomatic and high-risk asymptomatic women before cervical dilation occurs, using a 
fixed threshold of 50 ng/ml to define a positive and negative result (qualitative test) [9]. fFN 
is a glycoprotein thought to contribute to the adhesion between chorionic and decidual 
tissue in pregnancy. Prior to preterm birth, disturbance of the integrity of the maternal-fetal 
interface, particularly the partial separation of the decidua from the fetal membranes, is 
believed to result in release of fFN into the CVF fluid. More recently, enhanced prediction 
has been demonstrated using a quantitative bedside test (qfFN, Hologic 10Q system) which 
provides additional incremental thresholds to define variable risk [10,11].
It is not known however whether CVF qfFN concentrations are uniformly raised after 
cervical dilation and membranes exposure has occurred, or whether the test may still be 
predictive of outcome in these circumstances and according to concentration. In view of the 
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high risk of sPTB in this group [6] and qfFN testing being now available at the bedside, an 
accurate prediction of clinical outcome would be useful and could help direct emergency 
obstetric management. The purpose of this study was to assess the predictive value of CVF 
qfFN in women with BFM to predict sPTB within 14 days of presentation and before 34 
weeks of gestation.
MATERIALS AND METHODS
This was a predefined secondary analysis of a larger prospective cohort study (EQUIPP; 
Evaluation of Quantitative fetal fibronectin in Prediction of Preterm birth) of CVF qfFN 
concentration in women at high risk of sPTB, conducted between October 2010 and August 
2014 at five UK tertiary referral centres.
Ethical approval was granted by the South East London Research Ethics Committee, and all 
local research ethics committees that were associated with participating centres. Women 
were recruited to the study if they had singleton pregnancies, and were considered high-risk 
for preterm birth (one or more of: previous sPTB <37 weeks’ gestation; previous second-
trimester miscarriage ≥16 weeks; previous invasive cervical surgery; uterine abnormality; 
incidental finding of a short cervix <25 mm or symptoms suggestive of preterm labour or 
bulging membranes e.g. abdominal pain, vaginal pressure, increased discharge). Women 
were enrolled in this sub-analysis at the time they had BFM noted at speculum (any degree 
of cervical dilatation), if they were between 18 and 32 weeks of gestation, were not 
contracting, and underwent both quantitative (Hologic Rapid fFN 10Q) and qualitative 
(single-threshold Hologic Rapid fFN TLiIQ) fFN concentration measurements. fFN testing was 
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performed prior to ultrasound scan or digital examination using previously described 
methods, in line with the manufacturer’s guidelines [10]. Briefly, during speculum 
examination, a swab was inserted into the posterior fornix and rotated for 10 seconds until 
saturated, avoiding the cervix and fetal membranes. A single aliquot (200 μl) of the sample 
was analysed with the conventional qualitative analyser, and another with the quantitative 
one. The two tests were run concurrently and clinicians were made aware of the qualitative 
result, whereas the quantitative one was blinded (by generation of a 3 letter code). Women 
with blood stained CVF samples, sexual intercourse in the previous 24 hours, or 
suspected/confirmed rupture of membranes were excluded from the analysis, due to 
known interference with fFN measurement. Women with iatrogenic delivery prior to the 
outcome gestation of interest were excluded. Because of the technical difficulty and 
variability in recording cervical dilation with bulging fetal membranes, this was not included 
as a further parameter in our analysis.
The primary outcome for analysis was sPTB within 14 days from testing, with additional 
outcomes of sPTB prior to 34 weeks of gestation and time from testing to delivery. 
Statistical analysis was performed with SPSS v22 (Statistical Package for the Social Science, 
IBM). Previously established thresholds of qfFN (10, 50, 200, 500 ng/ml) [10,11] were used 
to determine sensitivity, specificity, positive and negative predictive values, likelihood ratios 
and relative risk for sPTB within 14 days and <34 weeks of gestation. Receiver operating 
characteristic (ROC) curves were calculated for both qualitative and quantitative fFN 
measurements. Further subgroup analysis was conducted based on gestational age at 
presentation: early (18-22 weeks), intermediate (23-27 weeks) and advanced (28-32 weeks). 
Variables are presented as median (lower quartile-upper quartile), mean ± standard 
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deviation, or frequency (percentage) where appropriate. This study is reported according to 
the Standards for the Reporting of Diagnostic accuracy studies (STARD) guidelines.
RESULTS
66 women fulfilling the inclusion criteria presented with BFM noted at speculum, of the 
2571 high-risk women screened. Three were excluded due to blood staining of the CVF 
sample and one due to regular painful contractions at presentation (Figure 1). None had 
recent sexual intercourse and membranes were all visualised intact; there were no 
iatrogenic deliveries prior to 34 weeks of gestation. The demographic and clinical 
characteristics of the 62 women eligible for analysis are described in Table 1. Median 
gestational age was 24+0 weeks (LQ-UQ, 21+2-25+3) at presentation and 34+4 weeks (25+2-
39+0) at delivery. 9/62 women (15%) presented with symptoms of bulging membranes (e.g. 
abdominal pain, vaginal pressure, increase  discharge); the rest (85%) were incidentally 
discovered on speculum examination at routine clinical surveillance appointment. 29 (47%) 
women presented with a vaginal cerclage already in situ (history or ultrasound indicated 
cerclage earlier in the pregnancy), while 14 (23%) underwent rescue cerclage soon after 
presentation (all of whom were <24 weeks’ at presentation). 13 women (21%) delivered 
spontaneously within 14 days of presentation, and 30 (48%) did so before 34 weeks of 
gestation.
Levels of fFN in CVF were measured in all 62 women, both with the quantitative system and 
with the qualitative test. Table 2 describes the distribution of women in each qfFN category 
and the rates of sPTB in each group. Two thirds of women with fFN ≥500 ng/ml had sPTB 
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within 14 days of testing, compared to 7% of those with fFN 10-49 ng/ml. No women with 
qfFN concentration <10 ng/ml delivered within 14 days.
The median time to delivery from fFN measurement was 58 days (17-110). When those who 
had a rescue cerclage at presentation were excluded, median time to delivery was 44 days 
(14-116). Spearman’s rank-order correlation was significant between fFN concentration at 
presentation and number of days to delivery (rs=-0.615, p<0.001), which appeared to follow 
a logarithmic trend (Figure 2). Mann-Whitney U analysis demonstrated a significant 
difference in the distribution of qfFN concentrations in women who delivered preterm 
compared to those who did not, both within 14 days from testing (p=0.001) and <34 weeks 
(p<0.001). Figure 3 shows the ROC curves for prediction of sPTB using qfFN, as well as the 
traditional qualitative test.
For prediction of sPTB within 14 days from testing, the area under the ROC curve (AUROC) 
for qfFN was 0.81 (95% CI 0.69-0.94), while that of the qualitative system was 0.68 (95% CI 
0.53-0.83). For prediction of sPTB <34 weeks of gestation, the AUROC for qfFN was 0.84 
(95% CI 0.73-0.95), and 0.76 for the qualitative test (95% CI 0.64-0.88).
Predictive statistics for sPTB within 14 days and prior to 34 weeks of gestation using qfFN 
are described in Tables 3 and 4 respectively. For delivery within 14 days, fFN10ng/ml had 
100% sensitivity, while fFN500 ng/ml had 94% specificity.
These parameters did not differ significantly across subgroups of early (18-22 weeks), 
intermediate (23-27 weeks) and advanced (28-32 weeks) gestational age at presentation. 
The AUROCs for qfFN were respectively 0.83, 0.79, 0.75 for sPTB within 14 days, and 0.88, 
0.82, 0.56 for sPTB <34 weeks.
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When women who received rescue cerclage after presentation were excluded, ROC curves 
for prediction of sPTB <14 days and before 34 weeks of gestation subtended areas of 0.85 
(95% CI 0.72-0.97) and 0.81 (95% CI 0.68-0.95) respectively. Further subgroup analysis was 
not conducted due to small numbers.
COMMENT
This study demonstrates the prognostic value of the qfFN assay to predict sPTB – both 
within 14 days of testing and before 34 weeks of gestation – in women with bulging 
membranes at extremely high risk of preterm birth. Our results show that the risk of 
preterm birth correlates with qfFN concentration in CVF even in women with BFM, a group 
traditionally thought to be at universally high risk of preterm birth. This might suggest that 
leakage of fFN into the CVF could be an active secretory process, related to risk of delivery 
following disruption of the maternal-fetal interface, rather than a passive mechanism 
initiated solely as a result of proximity of exposed fetal membranes to the vagina.
Women with BFM but very low concentrations of CVF qfFN have a low risk of subsequent 
delivery within 14 days of presentation compared with women with higher concentrations 
of qfFN (RR=9.3, 95% CI 1.3-65.2). In this cohort with BFM, no women with qfFN <10 ng/ml 
delivered within 14 days, while a quarter of those with qfFN concentrations 200 ng/ml and 
two thirds of women with qfFN ≥500 ng/ml delivered within this time frame. AUROCs for 
prediction of sPTB within 14 days from testing (0.81) and <34 weeks’ gestation (0.84) 
demonstrate strong discriminatory power even in the presence of BFM. Furthermore, the 
positive prediction of qfFN at thresholds of 200 ng/ml was superior to the traditionally used 
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qualitative test (threshold of 50 ng/ml), whilst maintaining good negative prediction. Our 
subgroup analysis showed that these results remained consistent across early, intermediate 
and advanced gestational age groups. This is particularly reassuring in those who presented 
between 18 and 22 weeks’ gestation, a high-risk group in which early intervention would be 
strongly considered. Sub-analysis was limited by our small study population, particularly for 
women of advanced gestational age at presentation (n=9), which could explain the decrease 
in the AUROCs for qfFN in this group.
Data collected prospectively onto a dedicated trial database ensured accuracy, and 
clinicians were blinded to the quantitative fFN concentration, so that management decisions 
were not influenced by the result. In spite of this unique group of very high-risk women, 
BFM is a rare event, limiting the ability to perform highly powered predictive statistics.
Furthermore, 23% of our cohort received a rescue cervical cerclage, which might have 
delayed delivery and resulted in fewer events overall than expected. This would have 
reduced the calculated PPV, which could therefore be even higher than 67% without 
cerclage in situ. The ROC areas in the group without emergency cerclage are indeed 
reassuring. Of note, it was not standard practice in the United Kingdom to routinely 
prescribe progesterone to high-risk women, nor women with BFM.
To our knowledge, there have been no other studies evaluating the relationship between 
CVF qfFN concentration and subsequent preterm birth in this extremely high-risk group of 
women with BFM. Our group has previously demonstrated the predictive value of 
quantitative fFN measurement in women presenting with symptoms of preterm labour, 
with added risk discrimination over and above the traditional qualitative test [10], as well as 
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in asymptomatic women at high risk of preterm birth [11]. However, women with bulging 
fetal membranes were excluded from those analyses.
In this study, prediction of sPTB using qfFN compares favourably to high-risk cohorts 
described in the literature. For example, <2% (3/170) of those with qfFN concentrations <10 
ng/ml delivered within 14 days in a group of women with a closed cervix (<2cm dilated) and 
symptomatic for threatened preterm labour [10], similar to our BFM cohort (0/11). In 
symptomatic women with fFN concentration 500 ng/ml and a closed cervix, risk of sPTB 
within 14 days was 46% (6/13) [10], compared to 67% (6/9) of women in our cohort with 
BFM.
The high risk of preterm delivery in our study population is reflected in the distribution of 
fFN concentrations detected. We found a uniquely high proportion of women with qfFN 
concentration 500 ng/ml (15%), compared with other studies of qfFN where 
concentrations 500 ng/ml (1-5%) [10,11] or even 300 ng/ml (10%) [12] are usually rare. 
Conversely, only 18% of women in our cohort had very low (<10 ng/ml) qfFN 
concentrations, compared to 57% reported in symptomatic women without BFM [10].
We confirm the clinical role of this bedside assay for the prediction of sPTB even in the 
context of BFM, suggesting that an active process could underlie fFN release. Whilst further 
larger studies are needed to validate these findings and evaluate their use in clinical 
practice, qfFN concentrations could potentially guide decisions such as in-utero transfer to 
specialist neonatal units, magnesium sulphate for neuroprotection, and steroid 
administration. The use of multiple thresholds could allow clinicians to alter decision-making 
based on a risk-benefit ratio for different interventions. For example, given that the 
beneficial effects of antenatal corticosteroids, routinely given to women with BFM, are lost 
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after 7 days [3] and repeated courses after this timeframe have been shown to reduce 
morbidity in preterm infants but with adverse effects on fetal growth [13], accurate timing 
is essential. qfFN could be a useful guide to target the group at highest risk, and avoid 
premature dosing. Given the high failure rate of rescue cerclage and the potential for 
morbidity associated with surgery and foreign materials, qfFN could be used to assist in the 
decision to insert cerclage. In women who present with bulging fetal membranes, qfFN can
help to risk discriminate those likely to deliver soon.
Page 14 of 25
Ac
ce
pte
d M
an
us
cri
pt
13
CONTRIBUTIONS TO AUTHORSHIP
Conception and design of study: AHS; data acquisition: FF, AI; analysis and interpretation: 
FF, AI, NLH; drafting and editing of manuscript: FF, AI, NLH, AHS; recruitment and collection 
of CVF samples: NLH, AHS.
CONFLICTS OF INTEREST
Prof. Shennan and Dr. Hezelgrave received financial assistance providing educational talks 
on preterm birth from Hologic, USA. Prof. Shennan is a member of the European and 
Australian perinatal advisory board facilitated by Hologic USA, and a co-investigator of a trial 
evaluating the use of fetal fibronectin testing for prediction of preterm birth (funding: 
Wellbeing of Women, fetal fibronectin test kits provided by Hologic, USA).
The other authors report no conflict of interest.
Part of this work in abstract form has been presented at the British Maternal and Fetal 
Medicine Society’s 17th annual conference, London, UK, 23-24 April 2015.
FUNDING
This study was funded by Tommy’s Baby Charity and the NIHR Biomedical Research Centre 
at Guy’s and St Thomas’ NHS Trust (London, UK).
Page 15 of 25
Ac
ce
pte
d M
an
us
cri
pt
14
REFERENCES
[1] Liu L, Johnson HL, Cousens S, Perin J, Scott S, Lawn JE, et al. Global, regional, and 
national causes of child mortality: An updated systematic analysis for 2010 with time 
trends since 2000. Lancet 2012;379:2151–61. doi:10.1016/S0140-6736(12)60560-1.
[2] Blencowe H, Vos T, Lee AC, Philips R, Lozano R, Alvarado MR, et al. Estimates of 
neonatal morbidities and disabilities at regional and global levels for 2010: 
introduction, methods overview, and relevant findings from the Global Burden of 
Disease study. Pediatr Res 2013;74 Suppl 1:4–16. doi:10.1038/pr.2013.203.
[3] Roberts D, Dalziel S. Antenatal corticosteroids for accelerating fetal lung maturation 
for women at risk of preterm birth. Cochrane Database Syst Rev 2006:CD004454. 
doi:10.1002/14651858.CD004454.pub2.
[4] Shlossman PA, Manley JS, Sciscione AC, Colmorgen GH. An analysis of neonatal 
morbidity and mortality in maternal (in utero) and neonatal transports at 24-34 
weeks’ gestation. Am J Perinatol 1997;14:449–56. doi:10.1055/s-2007-994178.
[5] Althuisius SM, Dekker GA, Hummel P, Van Geijn HP. Cervical incompetence 
prevention randomized cerclage trial: Emergency cerclage with bed rest versus bed 
rest alone. Am J Obstet Gynecol 2003;189:907–10. doi:10.1067/S0002-
9378(03)00718-X.
[6] Daskalakis G. Management of Cervical Insufficiency and Bulging Fetal Membranes. 
Obstet Gynecol 2006;107:1422. doi:10.1097/01.AOG.0000220658.12735.c6.
[7] Olatunbosun OA, Al-Nuaim L, Turnell RW. Emergency cerclage compared with bed 
rest for advanced cervical dilatation in pregnancy. Int Surg 1995;80:170–4.
[8] Anderson-Knight HE, Hezelgrave NL, Shennan a. H. Spontaneous resolution of a
midtrimester dilated cervix with expectant management guided by quantitative foetal 
fibronectin results. J Obstet Gynaecol 2015:1–2. 
doi:10.3109/01443615.2015.1006597.
[9] Berghella V, Hayes E, Visintine J, Baxter Jason K. Fetal fibronectin testing for reducing 
the risk of preterm birth. Cochrane Database Syst Rev 2008. 
doi:10.1002/14651858.CD006843.pub2.
[10] Abbott DS, Radford SK, Seed PT, Tribe RM, Shennan AH. Evaluation of a quantitative 
fetal fibronectin test for spontaneous preterm birth in symptomatic women. Am J 
Obstet Gynecol 2013;208:122.e1–6. doi:10.1016/j.ajog.2012.10.890.
Page 16 of 25
Ac
ce
pte
d M
an
us
cri
pt
15
[11] Abbott DS, Hezelgrave NL, Seed PT, Norman JE, David AL, Bennett PR, et al. 
Quantitative Fetal Fibronectin to Predict Preterm Birth in Asymptomatic Women at 
High Risk. Obstet Gynecol 2015;125:1168–76. doi:10.1097/AOG.0000000000000754.
[12] Goepfert AR, Goldenberg RL, Mercer B, Iams J, Meis P, Moawad A, et al. The Preterm 
Prediction Study: Quantitative fetal fibronectin values and the prediction of 
spontaneous preterm birth. Am J Obstet Gynecol 2000;183:1480–3. 
doi:10.1067/mob.2000.107067.
[13] Crowther CA, McKinlay CJ, Middleton P, Harding JE. Repeat doses of prenatal 
corticosteroids for women at risk of preterm birth for improving neonatal health 
outcomes. Cochrane Database Syst Rev 2011:CD003935. 
doi:10.1002/14651858.CD003935.pub3. 
Page 17 of 25
Ac
ce
pte
d M
an
us
cri
pt
16
FIGURE CAPTIONS
FIGURE 1. Study design
Standards for the Reporting of Diagnostic accuracy studies (STARD) flow chart.
BFM, bulging fetal membranes; qfFN, quantitative fFN system; TLi, qualitative fFN system; 
sPTB, spontaneous preterm birth.
FIGURE 2. Time to delivery as a function of fFN levels
Correlation between increasing values of fFN concentration and number of days elapsed 
from testing to delivery (n=62).
FIGURE 3. ROC curves: diagnostic performance of the two fFN tests
ROC curves for the prediction of sPTB within 14 days from testing (A) and before 34 weeks 
of gestation (B), for both the quantitative 10Q system (blue) and the qualitative TLiIQ system 
(green). The midline diagonal segment (red) represents the random classifier (area=0.5).
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Table 1. Demographic & clinical characteristics (n=62).
Characteristic Value
Age (years) 32 ± 6
BMI (kg/m2) 28 ± 5
Ethnicity
White
Black
Other
21 (34%)
36 (58%)
5 (8%)
Symptoms of bulging membranes 9 (15%)
Previous sPTB 19 (31%)
Previous premature pre-labour rupture of membranes 10 (16%)
Previous second-trimester miscarriage 26 (42%)
Previous cervical surgery 10 (16%)
Smoking
Current
Ex-smoker
Never
4 (6%)
9 (15%)
45 (73%)
History of domestic violence 4 (6%)
History of recreational drug use 4 (6%)
Median gestational age at testing 24+0 (21+2-25+3)
Median gestational age at delivery 34+4 (25+2-39+0)
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Data reported as mean ± SD, n (%), or median (LQ-UQ). sPTB, spontaneous preterm birth.
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Table 2. Distribution of women according to qfFN concentration and associated rates of 
sPTB.
Spontaneous preterm birth rate, n (%)
Quantitative fFN 
category (ng/ml)
N (%) Within
14 days <30 wks <34 wks <37 wks
<10 11 (18%) 0 (0%) 1 (9%) 2 (18%) 3 (27%)
10-49 14 (23%) 1 (7%) 1 (7%) 2 (14%) 4 (29%)
50-199 20 (32%) 4 (20%) 9 (45%) 11 (55%) 14 (70%)
200-499 8 (13%) 2 (25%) 3 (38%) 7 (88%) 7 (88%)
≥500 9 (15%) 6 (67%) 8 (89%) 8 (89%) 8 (89%)
Total 62 13 (21%) 22 (36%) 30 (48%) 36 (58%)
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Table 3. Prediction of spontaneous preterm birth within 14 days from testing.
Fetal fibronectin threshold
Predictive variable
10 ng/ml 50 ng/ml 200 ng/ml 500 ng/ml
Sensitivity (%) 100 92 62 46
Specificity (%) 22 49 82 94
Positive Predictive Value (%) 26 32 47 67
Negative Predictive Variable (%) 100 96 89 87
Likelihood ratios
Positive 1.29 1.81 3.35 7.54
Negative 0 0.16 0.47 0.57
Relative risk (95% CI) 1 2.8(0.4-22.5)
3.5
(0.4-32.8)
9.3
(1.3-65.2)
Area under ROC 0.81 (95% CI 0.69-0.94)
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Table 4. Prediction of spontaneous preterm birth before 34 weeks of gestation.
Fetal fibronectin threshold
Predictive variable
10 ng/ml 50 ng/ml 200 ng/ml 500 ng/ml
Sensitivity (%) 93 87 50 27
Specificity (%) 28 66 94 97
Positive Predictive Value (%) 55 70 88 89
Negative Predictive Variable (%) 82 84 67 59
Likelihood ratios
Positive 1.30 2.52 8.00 8.53
Negative 0.24 0.20 0.53 0.76
Relative risk (95% CI) 1 3.9(1.0-14.8)
6.1
(1.7-22.7)
6.2
(1.7-22.9)
Area under ROC 0.84 (95% CI 0.73-0.95)
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